Design and Development of Lysyl tRNA Synthetase Inhibitors, for the Treatment of Tuberculosis
Open Access
- 1 August 2025
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (15) , 16459-16482
Abstract
There is currently a public health crisis due to the rise of multidrug-resistant tuberculosis cases, as well as the rise in the number of deaths from tuberculosis. To achieve the United Nations Sustainable Development Goal of ending the tuberculosis epidemic by 2030, new treatments are urgently required. We previously reported the discovery of 49, a preclinical candidate that acted through inhibition of the Mycobacterium tuberculosis lysyl tRNA synthetase (LysRS). In this report, the full medicinal chemistry program is reviewed from the original hit through to the optimized lead. The work was guided by the first crystal structures of M. tuberculosis LysRS. The physicochemical and pharmacokinetic properties were optimized to afford compounds suitable for evaluation in mouse efficacy models of tuberculosis and with the potential for clinical development.Keywords
All Related Versions
Funding Information
- Wellcome Trust (094090, 100195/Z/12/Z)
- Bill and Melinda Gates Foundation (INV-004709, INV-004761, INV-010616, OPP 1177930, OPP1066891, OPP1191579)
This publication has 26 references indexed in Scilit:
- Emerging bedaquiline resistance: A threat to the global fight against drug-resistant tuberculosisJournal of Biosafety and Biosecurity, 2024
- UCSF ChimeraX : Tools for structure building and analysisProtein Science, 2023
- Exploration of aminoacyl-tRNA synthetases from eukaryotic parasites for drug developmentJournal of Biological Chemistry, 2022
- Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugsNature Communications, 2022
- Genome-wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosisCell, 2021
- Two-Way Regulation of MmpL3 Expression Identifies and Validates Inhibitors of MmpL3 Function in Mycobacterium tuberculosisACS Infectious Diseases, 2020
- Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656)Journal of Medicinal Chemistry, 2017
- Considerations for the design and reporting of enzyme assays in high-throughput screening applicationsPerspectives in Science, 2014
- Selective and Specific Inhibition of the Plasmodium falciparum Lysyl-tRNA Synthetase by the Fungal Secondary Metabolite CladosporinCell Host & Microbe, 2012
- A simple method for displaying the hydropathic character of a proteinJournal of Molecular Biology, 1982